According to the Tuojing Life announcement, the company's holding subsidiary, Wuhan Kanglu Biotechnology Co., Ltd., and its wholly-owned subsidiary Jiangxi Tuojing Life Technology Co., Ltd. have recently obtained medical device registration certificates issued by the State Drug Administration and the Jiangxi Drug Administration, respectively. Among them, Kanglu Biotech obtained the third class of in vitro diagnostic reagents: human CYP2D6*10 and other multi-gene test kits to help guide the individualized use of hypertensive drugs; Jiangxi Toujing obtained two second-class in vitro diagnostic reagents: type I collagen amino-terminal lengthening peptide test kit and beta-collagen special sequence determination kit, all used for auxiliary diagnosis of osteoporosis. The above registration certificate has enriched the company's product line layout, and the impact on future performance cannot yet be predicted.

According to the Tuojing Life announcement, the company's holding subsidiary, Wuhan Kanglu Biotechnology Co., Ltd., and its wholly-owned subsidiary Jiangxi Tuojing Life Technology Co., Ltd. recently obtained medical device registration certificates issued by the State Drug Administration and the Jiangxi Drug Administration, respectively. Among them, Kanglu Biotech obtained the third class of in vitro diagnostic reagents: human CYP2D6*10 and other multi-gene test kits to help guide the individualized use of hypertensive drugs; Jiangxi Toujing obtained two second-class in vitro diagnostic reagents: type I collagen amino-terminal lengthening peptide test kit and beta-collagen special sequence determination kit, all used for auxiliary diagnosis of osteoporosis. The above registration certificate has enriched the company's product line layout, and it is not yet possible to predict the impact on future performance.